Please login to the form below

pay-for-delay

This page shows the latest pay-for-delay news and features for those working in and with pharma, biotech and healthcare.

Tit for tat as PBMs blame pharma for high drug prices

The PBMs also cited “pay for delay” and other anti-competitive practices in the pharma industry such as withholding samples from generic manufacturers and tweaking formulations to extend patent life among ... In my experience, that kind of

Latest news

Concordia accused of overcharging NHS for thyroid drug

Last December, Pfizer and Flynn Pharma were ordered to pay £84m after being accused of charging excessive and unfair prices for anti-epilepsy treatment phenytoin sodium capsules, but have appealed the ... ruling. Meanwhile, earlier in 2016 the CMA fined
Lundbeck challenge to EC pay-for-delay ruling fails

The Celexa case judgment was the first in a broad investigation by the EC of pay-for-delay practices by the pharma industry that kicked off in 2010. ... After the Lundbeck case, the Commission fined companies in two other pay-for-delay investigations -
Pharma's reputation rises, but pricing still a sore point

Patient group survey sees the industry's corporate reputation increase. ViiV was ranked number 1 for the second year in a row . ... of transparency (particularly on pricing and side effects), pay-for-delay schemes and mismanagement of confidential
UK government fines GSK over 'pay-for-delay' deals

The culmination of the investigation is a £37.6m (around $55m) fine for GSK and smaller penalties for other companies involved in the 'pay-for-delay' scheme, including Merck KGaA and ... The CMA's decision relates to activities between 2001 and 2004 in
Servier announces job cuts as pressures mount

Management will mobilise all means available to minimise the social impact of this project and to identify, in consultation with staff representatives, the most appropriate support solutions for the employees concerned," ... The announcement comes after

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Will biosimilars ever catch on in the US?

US courts have ruled that some of the patent suit settlements amount to ‘pay-for-delay’ deals, in which the maker of the branded drug is essentially paying a potential biosimilar ... FTC. According to Michael A Carrier, a distinguished professor at
Pharma deals in May 2015

This is not the first such case for Teva, as the FTC also filed suit last September for an alleged pay for delay relating to AndroGel. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell therapies.